

# Research Letter

AIDS 2017, 31:2431–2433

## Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells

Cheila Rocha<sup>a,b</sup>, Joana Duarte<sup>a</sup>, Pedro Borrego<sup>a,c</sup>, Rita Calado<sup>a</sup>, José Maria Marcelino<sup>d</sup>, Rita Tendeiro<sup>b,e</sup>, Emília Valadas<sup>f</sup>, Ana Espada Sousa<sup>b</sup> and Nuno Taveira<sup>a,c</sup>

**Potent HIV-neutralizing antibodies are critical for vaccination and viral reservoir control. High levels of neutralizing antibodies characterize HIV-2 infection, a naturally occurring model of attenuated HIV disease with low-to-undetectable viremia. We found that HIV-2-specific antibody potency increased in direct association with the loss of both switched and unswitched memory B cells in untreated HIV-2 infection. Thus, HIV antibody affinity maturation is linked to memory B-cell exhaustion even in reduced viremia settings.**

The specificity and variability of antibodies (Abs) is achieved by affinity maturation through somatic hypermutation and clonal selection. This process proceeds for weeks after acute infections or vaccination. There is much debate about the mutation levels and chronic antigen exposure needed to generate broadly neutralizing Abs (bNAbs) against HIV-1 [1]. In adults, bNAbs usually take 2–4 years to develop and are associated with high viremia and low CD4<sup>+</sup> T-cell counts [2–7]. In contrast to HIV-1, most HIV-2-infected patients develop potent bNAb responses [8–12]. In addition, HIV-2 infection usually courses with undetectable viral load and very slow rate of CD4<sup>+</sup> T-cell decline even in the absence of antiviral treatment [13,14]. Therefore, understanding the generation of broad and potent neutralizing Abs in this unique model of naturally occurring control of viremia is relevant for the vaccine field.

We aim to investigate the relationship between memory B cells and neutralizing Ab (NAb) response in untreated HIV-2-infected adults. Previously, we have shown that these patients featured contraction of the memory B-cell compartment in direct association with the degree of CD4<sup>+</sup> T-cell depletion and markers of immune activation, suggesting the occurrence of lymphoid tissue disruption [15]. Here, we asked how this finding relates with HIV-2-specific Abs.

We analysed the NAb response in 27 untreated HIV-2-infected patients, included in a previous report [15]. Twenty-one patients (78%) had undetectable viral load (detectable in six patients, ranging from 1189 to 13 627

RNA copies/ml), and 20 (74%) had CD4<sup>+</sup> T-cell counts above 350 cells/ $\mu$ l (median 568, range 52–1511 cells/ $\mu$ l). Informed consent for blood collection and participation in the study was obtained from all participants, under the approval of the Ethical Board of the Faculty of Medicine, University of Lisbon. HIV-2 viremia was quantified by reverse transcriptase-PCR (detection threshold: 40 RNA copies/ml), as described previously [16,17]. The neutralizing activity was analysed in plasma against a panel of four heterologous primary CCR5-tropic isolates (03PTHCC6, 03PTHCC12, 03PTHCC19, 03PTHSM2). Origin and characterization of these isolates, and their sensitivity to IgG NAbs, have been described elsewhere [10,18,19]. A luciferase reporter gene assay in TZM-bl cells was used, as described previously [20,21]. Additionally, binding Abs against HIV-2 envelope glycoproteins gp125 (C2V3C3 region) and gp36 were quantified in samples from a subset of the patients using an ELISA HIV-2 assay as described previously [15,22]. Memory B-cell populations were assessed based on the expression of CD27 and surface IgD by flow cytometry, with class-switched memory B cells defined as CD19<sup>+</sup> CD27<sup>+</sup> IgD<sup>neg</sup> and unswitched memory B cells as CD19<sup>+</sup> CD27<sup>+</sup> IgD<sup>pos</sup>, as described previously [15]. Serum B-cell activating factor (BAFF) levels were quantified by ELISA as described previously [15]. Statistical analysis was performed with Prism, version 5.0 (GraphPad Software Inc., San Diego, California, USA). *P* values were two-tailed and significance was defined as *P* value less than 0.05. Linear regression was performed and Spearman correlation coefficients were computed.

All patients produced NAbs against the panel of four primary R5 isolates, with a median reciprocal log<sub>10</sub> IC<sub>50</sub> neutralization titer of 2.89 (interquartile range 2.76–3.18). NAb potency and breadth were directly associated (*N* = 27, Spearman rank, *r* = 0.4916, *P* = 0.0092; Supplemental Digital Content 1, <http://links.lww.com/QAD/B170>). Moreover, NAb potency and breadth were not associated with CD4<sup>+</sup> T-cell counts (*N* = 27, Spearman rank, *r* = -0.1902, *P* = 0.3419 and *r* = -0.0325, *P* = 0.8723, respectively). NAb potency has generally not been associated with the number of CD4<sup>+</sup> T cells in previous HIV-2 studies [9,12], except when patients representing the full spectrum of disease were analysed [10].

NAb potency increased in direct association with the increase in C2V3C3-specific binding Abs (*N* = 12, Spearman rank, *r* = 0.7250, *P* = 0.0098; Supplemental Digital Content 2 – blue, <http://links.lww.com/QAD/>


DOI:10.1097/QAD.0000000000001661

B170). However, no association was found between NAb potency and gp36-specific binding Abs ( $N=12$ , Spearman rank,  $r=0.4483$ ,  $P=0.1446$ ; Supplemental Digital Content 2 – black, <http://links.lww.com/QAD/B170>). Our findings confirm the presence of broad and potent NAbs targeting the C2V3C3-envelope region during chronic HIV-2 infection, as described previously [10].

NAb potency was found to increase significantly with the loss of switched ( $N=27$ , Spearman rank,  $r=-0.6436$ ,  $P=0.0003$ ) and unswitched ( $N=27$ , Spearman rank,  $r=-0.4162$ ,  $P=0.031$ ) memory B-cell populations (Fig. 1, top and bottom, respectively). In accordance with the association between NAbs and binding Abs, the loss of both switched and unswitched memory B-cell populations was directly correlated with the increase in C2V3C3-specific binding Abs ( $N=12$ , Spearman rank,  $r=-0.7622$ ,  $P=0.0055$  and  $r=-0.6434$ ,  $P=0.0278$ , respectively; Supplemental Digital Content 3, <http://links.lww.com/QAD/B170>). No association was found between switched and unswitched memory B-cell populations and gp36-specific binding Abs ( $N=12$ , Spearman rank,  $r=-0.5455$ ,  $P=0.0708$  and

$r=-0.2517$ ,  $P=0.4303$ , respectively; Supplemental Digital Content 3, <http://links.lww.com/QAD/B170>). No association was found between NAb titers and BAFF levels ( $N=11$ , Spearman rank,  $r=0.1455$ ,  $P=0.6731$ ; Supplemental Digital Content 4, <http://links.lww.com/QAD/B170>), despite the previous report of BAFF increase in parallel with B-cell disturbances in HIV-2 infected individuals [15].

To our knowledge, this is the first study addressing the relationship between NAb responses in HIV-2-infected patients and memory B-cell disturbances. In spite of the limitations imposed by the number of patients and sample availability that only allowed to test four viral isolates, we were able to reveal a strong direct association between memory B-cell exhaustion and the generation of NAbs as well as C2V3C3 binding Abs. These findings suggest that multiple rounds of HIV-2 infection are important for the generation of highly specific Abs, and that this happens at the expense of the memory B-cell pool. The lack of hypogammaglobulinemia [15] is likely because of the persistence of long-lived plasma cells, as shown in other clinical settings [23]. Although the levels of plasma viral load were reduced in HIV-2 infection even in the absence of antiretroviral therapy, we have shown that the extent of viral reservoirs is similar in HIV-2 and HIV-1 individuals [17,24]. Moreover, HIV-2 has been shown to infect and induce cytopathicity in lymphoid tissues [25], suggesting that there is contained local viral replication [26]. The prolonged time of infection that characterizes HIV-2 pathogenesis favors the continuous exposure to envelope antigens (either present in plasma viruses or bound to the surface of infected cells) and persistent immune activation [24]. This setting is ideal for the generation of highly specific Abs through affinity maturation, but ultimately leads to immune exhaustion.



**Fig. 1. Association between neutralizing antibodies and memory B cells.** Spearman's rank correlation coefficient was used to assess associations between neutralizing antibody titers and frequency of switched (CD27<sup>+</sup>IgD<sup>neg</sup>, top) and unswitched (CD27<sup>+</sup>IgD<sup>pos</sup>, bottom) memory within B cells ( $N=27$ ).

## Acknowledgements

N.T. and A.E.S. designed research. C.R., J.M.M., R.C., and R.T. performed experiments. C.R. and J.D. analyzed and interpreted the data. C.R. and P.B. performed the statistical analysis. E.V. contributed with patients' data. C.R., J.D., A.E.S., and N.T. wrote the article. All authors revised and approved the final manuscript.

The work was supported by grants PTDC/SAU-FAR/115290/2009, PTDC/SAU-EPI/122400/2010, and PIC/IC/82712/2007 from Fundação para a Ciência e Tecnologia (FCT) (<http://www.fct.pt>), Portugal and by Programa Operacional Ciência e Inovação 2010 (POCI2010). C.R., P.B., R.C., and R.T. were supported by PhD grants from FCT. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH:

TZM-bl from Dr John C. Kappes, Dr Xiaoyun Wu, and Tranzyme Inc.

## Conflicts of interest

There are no conflicts of interest.

<sup>a</sup>HIV Evolution, Epidemiology and Prevention, Research Institute for Medicines/Instituto de Investigação do Medicamento (iMed.U LISBOA), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal; <sup>b</sup>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon; <sup>c</sup>Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, Almada; <sup>d</sup>Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa (IHMT, UNL), Lisbon, Portugal; <sup>e</sup>Division of Infection and Immunity, UCL Institute of Immunity and Transplantation, London, UK; and <sup>f</sup>Serviço de Doenças Infecciosas, Faculdade de Medicina, Centro Hospitalar Lisboa Norte, Clínica Universitária de Doenças Infecciosas, Hospital de Santa Maria, Universidade de Lisboa, Lisbon, Portugal.

Correspondence to Nuno Taveira, PhD, HIV Evolution, Epidemiology and Prevention, Research Institute for Medicines/Instituto de Investigação do Medicamento (iMed.U LISBOA), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.  
E-mail: ntaveira@ff.ulisboa.pt

Received: 10 March 2017; revised: 14 September 2017; accepted: 22 September 2017.

## References

- Mascola JR, Haynes BF. **HIV-1 neutralizing antibodies: understanding nature's pathways.** *Immunol Rev* 2013; **254**:225–244.
- Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. **Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.** *J Virol* 2010; **84**:1631–1636.
- Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. **Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.** *J Infect Dis* 2010; **201**:1045–1053.
- Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. **Characteristics of the earliest cross-neutralizing antibody response to HIV-1.** *PLoS Pathog* 2011; **7**:e1001251.
- Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al., CAPRISA002 Study Team. **The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.** *J Virol* 2011; **85**:4828–4840.
- van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. **Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.** *AIDS* 2009; **23**:2405–2414.
- Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, et al. **Broadly neutralizing antibody responses in a large longitudinal Sub-Saharan HIV primary infection cohort.** *PLoS Pathog* 2016; **12**:e1005369.
- de Silva TI, Aasa-Chapman M, Cotten M, Hue S, Robinson J, Bibollet-Ruche F, et al. **Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.** *J Virol* 2012; **86**:930–946.
- Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, et al. **Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.** *J Virol* 2012; **86**:947–960.
- Marcelino JM, Borrego P, Nilsson C, Familia C, Barroso H, Maltez F, et al. **Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.** *AIDS* 2012; **26**:2275–2284.
- Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Now-roozalizadeh S, Esbjornsson J, et al. **Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.** *J Virol* 2012; **86**:961–971.
- Rodriguez SK, Sarr AD, MacNeil A, Thakore-Meloni S, Gueye-Ndiaye A, Traore I, et al. **Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1) and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.** *J Virol* 2007; **81**:5331–5338.
- Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. **Reduced rate of disease development after HIV-2 infection as compared to HIV-1.** *Science* 1994; **265**:1587–1590.
- Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. **Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.** *AIDS* 2008; **22**:457–468.
- Tendeiro R, Fernandes S, Foxall RB, Marcelino JM, Taveira N, Soares RS, et al. **Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.** *AIDS* 2012; **26**:1607–1617.
- Soriano V, Gomes P, Heneine W, Holguin A, Doruana M, Antunes R, et al. **Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load.** *J Med Virol* 2000; **61**:111–116.
- Soares RS, Tendeiro R, Foxall RB, Baptista AP, Cavaleiro R, Gomes P, et al. **Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients.** *J Virol* 2011; **85**:2429–2438.
- Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, et al. **The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.** *Retrovirology* 2008; **5**:78.
- Borrego P, Calado R, Marcelino JM, Bartolo I, Rocha C, Cavaco-Silva P, et al. **Baseline susceptibility of primary HIV-2 to entry inhibitors.** *Antivir Ther* 2012; **17**:565–570.
- Rocha C, Calado R, Borrego P, Marcelino JM, Bartolo I, Rosado L, et al. **Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.** *Retrovirology* 2013; **10**:110.
- Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N. **Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.** *J Virol* 2010; **84**:12429–12436.
- Marcelino JM, Barroso H, Goncalves F, Silva SM, Novo C, Gomes P, et al. **Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.** *J Clin Microbiol* 2006; **44**:607–611.
- Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. **Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.** *Blood* 2016; **128**:360–370.
- Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. **CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.** *J Immunol* 2002; **169**:3400–3406.
- Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, Goldsmith MA. **Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1.** *J Virol* 2000; **74**:9594–9600.
- Jobe O, Ariyoshi K, Marchant A, Sabally S, Corrah T, Berry N, et al. **Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection.** *Clin Exp Immunol* 1999; **116**:474–478.